-
Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
•
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its investigational drug YKYY015, targeting primary hypercholesterolemia or mixed hyperlipidemia characterized by elevated LDL-C levels. YKYY015, an siRNA drug, is distinctive for…
-
Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence
•
Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with Sinopharm Group Heilongjiang Co., Ltd., a major player in China’s pharmaceutical distribution sector. This collaboration is aimed at expanding Youcare’s market reach and resource pool, leveraging Sinopharm’s (HKG: 1099) extensive distribution channels and resource advantages.…
